RevealDx
RevealDx develops radiomics and AI-enabled decision support software for non-invasive lung cancer diagnosis. Its products are designed to help clinicians improve lung cancer outcomes by providing actionable insights from imaging data, aiming to reduce unnecessary procedures and associated risks.
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Healthcare, Artificial Intelligence, Medical Software
- Founded
- 2022 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Precision Medical Ventures Inc Seattle business license
- Stage
- Seed
- Founders
- Michael Calhoun, PhD
Is this your organization? Claim it
GeekWire 2026 Innovation of the Year Finalists Include Alpenglow Biosciences and Pacific Northwest National Laboratory
The 2026 GeekWire Awards announced finalists for Innovation of the Year, including Alpenglow Biosciences, Pacific Northwest National Laboratory, RevealDx, Starcloud, and VerAvanti, recognized for breakthroughs in healthcare and data center technology. The awards event will be held on May 7 in Seattle, with public voting open through April 10.
Seattle Startup RevealDx Raises $4.25M to Improve Lung Cancer Diagnosis with AI Technology
Seattle startup RevealDx raised $4.25 million to enhance lung cancer diagnosis using machine learning to analyze chest CT scans, aiming to accelerate diagnosis and reduce false positives. The company, formerly Mindshare Medical, is expanding in Europe and pursuing FDA approval in the U.S.
